Swiss National Bank Purchases 23,000 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Swiss National Bank boosted its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 8.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 287,900 shares of the company’s stock after acquiring an additional 23,000 shares during the period. Swiss National Bank owned 0.14% of Allogene Therapeutics worth $613,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ALLO. MML Investors Services LLC acquired a new stake in shares of Allogene Therapeutics in the 3rd quarter worth about $56,000. EP Wealth Advisors LLC increased its holdings in Allogene Therapeutics by 125.6% during the 3rd quarter. EP Wealth Advisors LLC now owns 24,475 shares of the company’s stock worth $69,000 after purchasing an additional 13,625 shares in the last quarter. Erste Asset Management GmbH purchased a new stake in shares of Allogene Therapeutics in the third quarter worth approximately $91,000. Intech Investment Management LLC bought a new position in shares of Allogene Therapeutics in the third quarter valued at approximately $116,000. Finally, BNP Paribas Financial Markets boosted its position in shares of Allogene Therapeutics by 541.5% during the third quarter. BNP Paribas Financial Markets now owns 46,374 shares of the company’s stock valued at $130,000 after buying an additional 39,145 shares during the last quarter. Institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Stock Down 0.6 %

Shares of ALLO stock opened at $1.55 on Friday. The firm has a market cap of $336.76 million, a P/E ratio of -0.99 and a beta of 1.02. The company has a 50 day moving average of $1.86 and a 200-day moving average of $2.25. Allogene Therapeutics, Inc. has a 12-month low of $1.32 and a 12-month high of $4.45.

Allogene Therapeutics (NASDAQ:ALLO) last issued its earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.06. As a group, equities analysts expect that Allogene Therapeutics, Inc. will post -1.28 EPS for the current year.

Insider Activity at Allogene Therapeutics

In other news, CEO David D. Chang sold 46,668 shares of Allogene Therapeutics stock in a transaction on Friday, March 14th. The stock was sold at an average price of $1.96, for a total value of $91,469.28. Following the completion of the transaction, the chief executive officer now directly owns 5,276,569 shares in the company, valued at approximately $10,342,075.24. The trade was a 0.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Timothy L. Moore sold 14,746 shares of the business’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $1.71, for a total value of $25,215.66. Following the sale, the insider now owns 250,713 shares in the company, valued at approximately $428,719.23. The trade was a 5.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 104,866 shares of company stock worth $194,461. 24.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

ALLO has been the subject of a number of analyst reports. HC Wainwright lowered their price target on Allogene Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, March 19th. Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 target price on shares of Allogene Therapeutics in a report on Friday, March 14th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a research report on Friday, March 14th. Finally, Citizens Jmp raised shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a research report on Friday, March 14th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Allogene Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $9.29.

Allogene Therapeutics Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).